Blinatumomab (Blincyto) - Oncology Nurse Advisor

Blinatumomab (Blincyto)

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews blinatumomab (Blincyto), indicated for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Table of Contents

Slide 4: Dosage and Administration
Slide 16: Cautions, Effects, and Interactions
Slide 28: What to Tell Your Patient
Slide 36: Reference

Next hm-slideshow in Slides